433 related articles for article (PubMed ID: 38104104)
1. Harnessing immunotherapy for brain metastases: insights into tumor-brain microenvironment interactions and emerging treatment modalities.
Zhou D; Gong Z; Wu D; Ma C; Hou L; Niu X; Xu T
J Hematol Oncol; 2023 Dec; 16(1):121. PubMed ID: 38104104
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
[TBL] [Abstract][Full Text] [Related]
3. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.
Liu Q; Li J; Zheng H; Yang S; Hua Y; Huang N; Kleeff J; Liao Q; Wu W
Mol Cancer; 2023 Feb; 22(1):28. PubMed ID: 36750830
[TBL] [Abstract][Full Text] [Related]
4. B7-H3 in Brain Malignancies: Immunology and Immunotherapy.
Guo X; Chang M; Wang Y; Xing B; Ma W
Int J Biol Sci; 2023; 19(12):3762-3780. PubMed ID: 37564196
[TBL] [Abstract][Full Text] [Related]
5. CAR-T cell therapy in melanoma: A future success story?
Simon B; Uslu U
Exp Dermatol; 2018 Dec; 27(12):1315-1321. PubMed ID: 30288790
[TBL] [Abstract][Full Text] [Related]
6. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
[TBL] [Abstract][Full Text] [Related]
7. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
8. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
9. T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment.
Kwok D; Okada H
J Neurooncol; 2020 Apr; 147(2):281-295. PubMed ID: 32185647
[TBL] [Abstract][Full Text] [Related]
10. The Interplay between T Cells and Cancer: The Basis of Immunotherapy.
Chen C; Liu X; Chang CY; Wang HY; Wang RF
Genes (Basel); 2023 Apr; 14(5):. PubMed ID: 37239368
[TBL] [Abstract][Full Text] [Related]
11. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
Zhang P; Zhang Y; Ji N
Front Immunol; 2022; 13():927132. PubMed ID: 35874698
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy: an alternative promising therapeutic approach against cancers.
Gupta SL; Basu S; Soni V; Jaiswal RK
Mol Biol Rep; 2022 Oct; 49(10):9903-9913. PubMed ID: 35759082
[TBL] [Abstract][Full Text] [Related]
13. CAR-modified immune cells as a rapidly evolving approach in the context of cancer immunotherapies.
Faeq MH; Al-Haideri M; Mohammad TAM; Gharebakhshi F; Marofi F; Tahmasebi S; Modaresahmadi S
Med Oncol; 2023 Apr; 40(5):155. PubMed ID: 37083979
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for Glioblastoma: Current Progress and Challenges.
Yu MW; Quail DF
Front Immunol; 2021; 12():676301. PubMed ID: 34054867
[TBL] [Abstract][Full Text] [Related]
15. Management of Brain Metastases in the New Era of Checkpoint Inhibition.
Lauko A; Thapa B; Venur VA; Ahluwalia MS
Curr Neurol Neurosci Rep; 2018 Aug; 18(10):70. PubMed ID: 30121715
[TBL] [Abstract][Full Text] [Related]
16. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy.
Lindo L; Wilkinson LH; Hay KA
Front Immunol; 2020; 11():618387. PubMed ID: 33643299
[TBL] [Abstract][Full Text] [Related]
17. Local immunotherapy of glioblastoma: A comprehensive review of the concept.
Sabahi M; Salehipour A; Bazl MSY; Rezaei N; Mansouri A; Borghei-Razavi H
J Neuroimmunol; 2023 Aug; 381():578146. PubMed ID: 37451079
[TBL] [Abstract][Full Text] [Related]
18. Sophisticated genetically engineered macrophages, CAR-Macs, in hitting the bull's eye for solid cancer immunotherapy approaches.
Unver N
Clin Exp Med; 2023 Nov; 23(7):3171-3177. PubMed ID: 37278931
[TBL] [Abstract][Full Text] [Related]
19. Recent Advances in CAR-Based Solid Tumor Immunotherapy.
Shin MH; Oh E; Kim Y; Nam DH; Jeon SY; Yu JH; Minn D
Cells; 2023 Jun; 12(12):. PubMed ID: 37371075
[TBL] [Abstract][Full Text] [Related]
20. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
